Zoetis Inc. (NYSE:ZTS) EVP Sells $55,420.00 in Stock

Zoetis Inc. (NYSE:ZTS) EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. This trade represents a 2.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Roxanne Lagano also recently made the following trade(s):

• On Tuesday, February 11th, Roxanne Lagano sold 326 shares of Zoetis stock. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $160.03 on Friday. The company has a market cap of $71.66 billion, a price-to-earnings ratio of 29.26, a PEG ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The firm has a 50 day simple moving average of $166.86 and a 200 day simple moving average of $176.33. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.33.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.25%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is currently 36.56%.

Hedge Funds Weigh In On Zoetis

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Callahan Advisors LLC increased its position in Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock valued at $2,135,000 after acquiring an additional 6,221 shares during the period. Pensionfund Sabic increased its position in Zoetis by 55.6% in the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after acquiring an additional 4,000 shares during the period. CIBC Asset Management Inc increased its position in shares of Zoetis by 24.1% during the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock worth $38,617,000 after buying an additional 46,050 shares during the period. PFW Advisors LLC acquired a new stake in shares of Zoetis during the fourth quarter worth $1,764,000. Finally, Alberta Investment Management Corp increased its position in shares of Zoetis by 2,050.0% during the fourth quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock worth $4,904,000 after buying an additional 28,700 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ZTS has been the subject of a number of recent analyst reports. Stifel Nicolaus cut their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Morgan Stanley cut their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Piper Sandler upped their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. UBS Group initiated coverage on shares of Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. Finally, Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.